BPC-157 vs Enalapril
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
The blood pressure champion that helped millions breathe easier and live longer
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
Enalapril
10–20 mg/day
Frequency
BPC-157
Once daily
Enalapril
Once daily
Administration
BPC-157
Subcutaneous injection
Enalapril
Oral tablet
Cycle length
BPC-157
4-6 weeks
Enalapril
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
Enalapril
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
Enalapril
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Cardiovascular Health
Long-term Protection
Quality of Life
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
Enalapril
Molecular formula
C20H28N2O5
Molecular weight
376.4 g/mol
Half-life
Enalapril: 1 hour; Enalaprilat (active form): 11 hours effective half-life
Bioavailability
Approximately 60% oral bioavailability when taken by mouth
CAS number
75847-73-3
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Enalapril
Oral
2.5–5 mg
Once daily · Titrate over 1–2 weeks
FDA-approved starting dose. For high blood pressure, begin at 5 mg once daily; for heart failure, begin lower at 2.5 mg to avoid a big drop in blood pressure [4].
10–20 mg/day
Once or twice daily · Ongoing
Usual blood-pressure maintenance dose, taken once daily or split into two doses. The dose is raised gradually based on response [4].
40 mg/day
In two divided doses (20 mg twice daily) · Ongoing
Maximum dose. For heart failure the target is 20 mg twice daily; for high blood pressure up to 40 mg/day is the ceiling [4].
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Enalapril
Managing hypertension to prevent serious complications
Enalapril is particularly well-suited for individuals focused on managing hypertension to prevent serious complications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating heart failure and improving survival rates
Enalapril is particularly well-suited for individuals focused on treating heart failure and improving survival rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting organs from damage caused by high blood pressure
Enalapril is particularly well-suited for individuals focused on protecting organs from damage caused by high blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Enalapril
Common
- Dry cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
Serious
- Severe allergic reaction
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Enalapril
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Enalapril is an FDA-approved ACE inhibitor with safety data spanning over 40 years of clinical use and post-market surveillance in millions of hypertensive patients. Persistent dry cough occurs in 10-20% of patients, caused by kinase II inhibition and bradykinin accumulation. Hyperkalemia is a serious risk, particularly in renal impairment, diabetes, or concurrent NSAID/potassium-sparing diuretic use—potassium monitoring is essential. Angioedema (0.1-0.2%) is a rare but life-threatening emergency, absolute contraindication for future ACE inhibitor use. Hypotension can occur in volume-depleted patients or those on concurrent vasodilators. Acute kidney injury risk exists in patients with bilateral renal artery stenosis or single kidney. Fetal teratogenicity is well-documented in pregnancy.
Contraindications
- Pregnancy (causes serious fetal harm)
- History of angioedema with ACE inhibitors
- Severe renal dysfunction
- Concurrent use with certain other blood pressure medications
- Potassium supplementation without medical supervision
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Enalapril if...
- Managing hypertension to prevent serious complications
- Treating heart failure and improving survival rates
- Protecting organs from damage caused by high blood pressure